A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer - Full Text View

Purpose

The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg and 1000 mg OGX-427 Arms to control Arm.

Condition	Intervention	Phase
Urologic Neoplasms Metastatic Bladder Cancer Urinary Tract Neoplasms	Drug: OGX-427 600 mg Drug: OGX-427 1000 mg Drug: Placebo Drug: Gemcitabine Drug: Cisplatin Drug: Carboplatin	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma

Resource links provided by NLM:

Genetics Home Reference related topics: bladder cancer

MedlinePlus related topics: Bladder Cancer

Genetic and Rare Diseases Information Center resources: Transitional Cell Carcinoma

U.S. FDA Resources

Further study details as provided by OncoGenex Technologies:

Primary Outcome Measures:

Overall Survival (OS) [ Time Frame: Baseline to date of death by any cause (up to approximately 12 months) ]
OS is defined as the time from randomization to death from any cause; OS was censored on date of last contact for participants still alive at time of analysis.

Secondary Outcome Measures:

Number of Participants With Treatment-emergent Adverse Events (AEs), Serious AEs, and Grade 3 or Higher AEs [ Time Frame: From initiation of study drug to end of study (up to 8 months) ]
Treatment-emergent AEs are defined as and AE that occurred after the first dose of study drug up to 30 days after the last dose of study drug. AEs were graded using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Treatment-emergent AEs could have occurred during loading dose period, chemotherapy period, maintenance period, and treatment period A detailed summary of adverse events is located in the Reported Adverse Event Module.
Number of Participants With ≥ 1 Hematology Abnormality and ≥ 1 Grade 3 or Higher Hematology Abnormality [ Time Frame: Screening through End of Study Visit (Within 30 [±7] days following withdrawal of study treatment) ]
Number of Participants With ≥ 1 Chemistry Laboratory Abnormality and ≥ 1 Grade 3 or Higher Chemistry Laboratory Abnormality [ Time Frame: Screening through End of Study Visit (Within 30 [±7] days following withdrawal of study treatment) ]
Number of Participants With ≥ 1 Urinalysis Abnormality and ≥ 1 Grade 3 or Higher Urinalysis Abnormality [ Time Frame: Screening through End of Study Visit (Within 30 [±7] days following withdrawal of study treatment) ]
Best Objective Tumor Response [ Time Frame: Baseline to measured progressive disease (up to approximately 12 months) ]
Complete Response (CR): Complete disappearance of all measurable and non-measurable disease with no new lesions. Any pathological lymph node (target or non-target) must have a reduction in short axis to < 10 mm). All markers of disease must have normalized. Partial Response (PR): A decrease from baseline of ≥ 30% of the diameter(s) of all target measurable lesions with no unequivocal progression of non-measurable lesions and no new lesions. Stable Disease (SD): Does not qualify for CR, PR, or progression. Disease Progression (PD): If at least one of following criteria is met: 1. Appearance of any new lesion or site of disease. 2. A 20% increase in the sum of the diameter(s) of target measurable lesions over either the smallest sum observed or over baseline if no decrease during therapy has occurred. The sum must also demonstrate an absolute increase of at least 5 mm. 3. Unequivocal progression of non-target lesions alone.
Overall Response Rate (ORR) and Disease Control Rate [ Time Frame: Baseline to measured progressive disease (up to approximately 12 months) ]
Participants were defined as having an "overall response" if their best response is either confirmed CR, confirmed PR, unconfirmed CR or unconfirmed PR. ORR was defined as the percent of participants who had an overall response. Participants were defined as having "disease control" if their best response is confirmed CR, confirmed PR, unconfirmed CR, unconfirmed PR or SD. The disease control rate (DCR) was defined as the percent of participants with disease control. (See "Best Objective Tumor Response" Outcome Measure above for response category definitions.)
Duration of Overall Response Rate [ Time Frame: Baseline to measured progressive disease (up to approximately 12 months) ]
Overall response was defined has having a response of Complete Response (CR) or Partial Response (PR). (See "Best Objective Tumor Response" Outcome Measure above for response category definitions.) Duration of Response is defined as the duration from the first overall response to the first Stable Disease (SD) or Disease Progression (PD), whichever happens first. If no SD or PD, subject is censored at the last tumor assessment (prior to other anti-cancer therapy if applicable).
Progression-free Survival (PFS) [ Time Frame: Baseline to measured progressive disease (up to approximately 12 months) ]
PFS was defined as the time from randomization to the date of disease progression or death, whichever occurred first, before or after treatment discontinuation. For participants still on study and those who remained alive and had not progressed after treatment discontinuation, PFS was censored on the date of the last tumor assessment.
Change From Baseline in Serum Hsp27 levels by End of Treatment [ Time Frame: Baseline, End of Treatment (up to approximately 12 months) ]
End of Treatment is last non-hemolyzed observation up to last dose + 30 days. Includes unscheduled and additional treatment visits. Hemolyzed samples were excluded.
Change From Baseline in Serum Clusterin Levels by End of Treatment [ Time Frame: Baseline, End of Treatment (up to approximately 12 months) ]
End of Treatment is last observation up to last dose + 30 days. Includes unscheduled and additional treatment visits.
Change From Baseline in Circulating Tumor Cell (CTC) Count by End of Treatment [ Time Frame: Baseline, End of Treatment (up to approximately 12 months) ]
End of Treatment is last observation up to last dose + 30 days. Includes unscheduled and additional treatment visits.
Serum OGX-427 Cmax and Trough Levels [ Time Frame: Cycle 1 Day 1 through Cycle 6 Day 1, End of Treatment (up to approximately 12 months) ]
only C1 to C6, Ctrough and Cmax - as well report EOT Ctrough


Enrollment:	183
Study Start Date:	October 2011
Study Completion Date:	November 2014
Primary Completion Date:	November 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: OGX-427 600 mg Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (600 mg)	Drug: OGX-427 600 mg Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle. Other Name: apatorsen Drug: Gemcitabine Patients will receive gemcitabine (1000 mg/m^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug. Drug: Cisplatin Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug. Drug: Carboplatin Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
Experimental: OGX-427 1000 mg Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (1000 mg)	Drug: OGX-427 1000 mg Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle. Other Name: apatorsen Drug: Gemcitabine Patients will receive gemcitabine (1000 mg/m^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug. Drug: Cisplatin Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug. Drug: Carboplatin Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
Active Comparator: Placebo Standard chemotherapy (gemcitabine and cisplatin) in combination with placebo	Drug: Placebo Patients will receive three loading doses of placebo within a 9-day period. Following the loading dose period, patients will receive weekly placebo infusions (IV) on Days 1, 8 and 15 of each 21-day cycle. Drug: Gemcitabine Patients will receive gemcitabine (1000 mg/m^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug. Drug: Cisplatin Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug. Drug: Carboplatin Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.

Detailed Description:

Following 3 loading doses, participants receive chemotherapy and study drug on a 21-day cycle during the Treatment Period (Chemotherapy Period) until disease progression, completion of 6 cycles, toxicity or voluntary participant withdrawal. Participants who do not have documented disease progression and have completed a minimum of four cycles of chemotherapy continue to receive weekly Study Drug maintenance therapy during the Maintenance Period until disease progression or the participant fulfills one of the other reasons for withdrawal from protocol treatment, unless they have been discontinued from protocol treatment for unacceptable toxicity related to study drug. All participants have an End of Treatment (EOT) visit when they are withdrawn from all study treatment (chemotherapy and maintenance). All participants are followed until documented disease progression. Once disease progression is documented, participants enter a Survival Follow-up Period during which data are collected regarding further cancer therapy, secondary malignancy, and survival status.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age ≥ 18 years at the time of consent
Histologically documented metastatic or locally inoperable advanced transitional cell carcinoma (TCC) of the urinary tract (bladder, urethra, ureter and renal pelvis) (T4b, N2, N3 or M1 disease) NOTE: Certain mixed histologies that are predominately (≥ 50%) TCC are eligible: squamous, adenocarcinoma, and undifferentiated. Mixed undifferentiated histology requires immunohistochemistry (IHC) consistent with a TCC origin. Mixed small-cell histologies are excluded
Measurable disease defined as at least one target lesion that has not been irradiated and can be accurately measured in at least one dimension by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
No prior systemic chemotherapy with the following exceptions:
- Prior use of radiosensitizing single agent therapy is allowed
- Prior neoadjuvant and adjuvant chemotherapy may be allowed
Minimum of 21 days since prior major surgery or radiation therapy
Karnofsky performance status ≥ 70%
Required laboratory values at baseline:
- absolute neutrophil count (ANC) ≥ 1.5 x 10^9 cells/L
- platelet count ≥ 125 x 10^9/L
- calculated creatinine clearance ≥ 60 mL/minute
- bilirubin ≤ 1.5 x upper limit of normal (ULN; ≤ 2.5 x ULN if secondary to Gilbert's disease)
- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN
If of child-bearing potential, willing to use contraceptives
Willing to give written informed consent

Exclusion Criteria:

A candidate for potential curative surgery or radiotherapy
Intravesical therapy within the last 3 months
Documented brain metastasis or carcinomatous meningitis, treated or untreated. NOTE: Brain imaging is not required unless the patient has symptoms or physical signs of central nervous system (CNS) disease.
Peripheral neuropathy ≥ Grade 2
Known serious hypersensitivity to gemcitabine, cisplatin or carboplatin
Current serious, uncontrolled medical condition such as congestive heart failure, angina, hypertension, arrhythmia, diabetes mellitus, infection, etc. or any condition such as a psychiatric illness which in the opinion of the investigator would make the patient unacceptable for the protocol
Cerebrovascular accident, myocardial infarction or pulmonary embolus within 6 months of randomization
Active second malignancy (except non-melanomatous skin cancer): active secondary malignancy is defined as a current need for cancer therapy or a high possibility (> 30%) of recurrence during the study
Pregnant or nursing (must have a negative serum or urine pregnancy test within 72 hours prior to randomization)
Participating in a concurrent clinical trial of an experimental drug, vaccine or device. Participation in an observational study is allowed

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01454089

Show 55 Study Locations

Sponsors and Collaborators

OncoGenex Technologies

PRA Health Sciences

Investigators


Principal Investigator:	Daniel Petrylak, MD	Columbia University

More Information


Responsible Party:	OncoGenex Technologies
ClinicalTrials.gov Identifier:	NCT01454089 History of Changes
Other Study ID Numbers:	OGX-427-02
Study First Received:	October 5, 2011
Last Updated:	October 6, 2016

Keywords provided by OncoGenex Technologies:


bladder urinary tract transitional cell carcinoma metastatic bladder cancer chemotherapy

Additional relevant MeSH terms:


Neoplasms Urinary Bladder Neoplasms Carcinoma, Transitional Cell Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Urinary Bladder Diseases Urologic Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Gemcitabine	Cisplatin Carboplatin Antineoplastic Agents Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 24, 2017